Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Appoints Marc Stapley as Senior Vice President and CFO

Published: Thursday, January 05, 2012
Last Updated: Thursday, January 05, 2012
Bookmark and Share
Stapley brings multi-national experience in high-growth and mature industries.

Illumina, Inc. has announced that it has named Marc Stapley, former Senior Vice President, Finance, at Pfizer and Americas Chief Financial Officer at Alcatel-Lucent, to the position of Senior Vice President and Chief Financial Officer.

Stapley will report to President and Chief Executive Officer Jay Flatley and will oversee Illumina’s finance, accounting, facilities and investor relations functions.

He will also become part of Illumina’s executive management team, which is responsible for directing all aspects of company strategy, planning and operations.

“Marc is an ideal fit for the fast-paced culture of Illumina,” said Jay Flatley. “He is a dynamic finance leader whose experience spans leading high-tech and pharmaceutical companies where he has helped transform the finance functions, directed ERP implementations, effectively identified cost reduction initiatives and led acquisition integration efforts.”

“I am honored to take the role of Illumina’s CFO and join such a world-class team,” said Stapley.

Stapley continued, “The Company is in a critical growth and development stage, and I look forward to supporting the continued innovation and performance that the company has delivered over many years.”

Stapley joins Illumina from Pfizer where he served as Senior Vice President responsible for global financial processes and systems, leading integration efforts in both the Wyeth and King Pharmaceutical acquisitions and providing oversight to the company’s largest technology investment program.

Prior to Pfizer, he served in a variety of senior finance roles at Alcatel-Lucent, including Americas CFO. He also worked as Finance Director and Controller for several groups at Cadence Design Systems.

Stapley began his career as an Auditor at Coopers & Lybrand. Stapley holds a First Class BSc (Honors) in Mathematics from The University of Reading (England) and is a member of the Institute of Chartered Accountants in England and Wales.

Stapley is expected to join Illumina on January 20, 2012. At that time he will assume the CFO responsibilities currently held by Christian Henry.

Henry, who for the past two years has been serving in both the CFO role and as GM of the Company’s Genetic Analysis business (formerly Life Sciences), will now be able to fully dedicate his time to leading our Genetic Analysis business.

“I would like to thank Christian for the outstanding contributions he has made to Illumina in the CFO role,” said Jay Flatley.

Flatley continued, “Since 2005, Christian has developed a world-class finance organization and led multiple corporate financings, acquisitions and facility relocations. I look forward to the impact he can make by solely focusing on driving our Genetic Analysis Business.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina, FlowJo Partner
Companies to develop software for analysis and reporting of single cell data will advance research into cell function, disease progression, and therapeutic response.
Thursday, August 11, 2016
Illumina and 10x Genomics Announce Co-Marketing Relationship
Illumina and 10x Genomics have announced building partnership to promote 10x Genomics linked-read sequencing products and Illumina sequencing systems.
Thursday, February 11, 2016
Illumina Files Patent Infringement Suit in the UK Against Premaitha Health
Suit is filed for Infringement of NIPT Patents.
Monday, March 16, 2015
Illumina Revenues Jump 35 Percent
Company’s Third Quarter 2014 Results Announced.
Tuesday, October 21, 2014
Initial Companies Focused on Breakthrough Applications in Therapeutics, Agriculture, and Molecular Pathology
The selection of three startup companies for the inaugural Illumina Accelerator funding cycle are announced.
Wednesday, October 15, 2014
Illumina's HiSeq X Ten Sequencing Technology for Population Studies
Next-generation sequencing technologies to be implemented at new High-Throughput Genomics Center for the MENA region.
Tuesday, July 22, 2014
Illumina Announces Pricing of Convertible Senior Notes
The Notes are being offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").
Monday, June 09, 2014
Novogene Acquires an Illumina HiSeq X Ten Sequencing System
First-in-China deal Iincreases Novogene's investment in Illumina's Next-Generation Sequencing technology.
Thursday, February 13, 2014
Illumina Announces Recipients of Agricultural Greater Good Initiative Grants
Expanded program focuses on improving food security and furthering agricultural sustainability.
Wednesday, January 16, 2013
Illumina Awarded FDA Contract for NGS Technology to Identify Foodborne Pathogens
Agency selects MiSeq® system for program to explore NGS as mechanism to enhance food safety.
Wednesday, September 19, 2012
The Broad Institute Joins the Illumina Genome Network
Partnership expands the network’s capabilities to enable sequencing of previously inaccessible samples.
Tuesday, June 05, 2012
Cold Spring Harbor Laboratory Joins the Illumina Genome Network
Partnership expands access to large-scale whole genome sequencing.
Monday, May 28, 2012
Macrogen, Inc. Increases Investment in Illumina’s Next-Generation Sequencing Technology
New purchase includes ten HiSeq 2000®Systems, HiSeq 2500® upgrades, and two MiSeq®Systems.
Thursday, March 22, 2012
Illumina Comments on Roche’s Unsolicited Tender Offer Extension
Roche to acquire all outstanding shares of Illumina for $44.50 in cash per common share.
Monday, February 27, 2012
Illumina's Board Unanimously Rejects Roche's Unsolicited Tender Offer
Urges stockholders not to tender their shares, company considers offer inadequate.
Wednesday, February 08, 2012
Scientific News
Shedding Light on HIV Vaccine Design
Broadly speaking - Mathematical modelling of host-pathogen coevolution sheds light on HIV vaccine design.
AACC 2016 Sees Clinical Chemistry Labs Drive Precision Medicine Offerings
Biomarker assays to enable precision medicine and risk assessment, mass spec-based tests designed for use in clinical labs large and small, and liquid biopsy technology captured the spotlight at the AACC annual meeting.
Automated Patch Clamping Trends
Learn more about current practices, preferences and metrics in ion channel drug screening using APC technology.
Lab-on-a-Stick: Miniaturised Clinical Testing For Fast Detection Of Antibiotic Resistance
A portable power-free test for the rapid detection of bacterial resistance to antibiotics has been developed by academics at Loughborough University and the University of Reading.
Genetic Ancestry of Cultivated Strawberry Unravelled
UNH scientists constructed a linkage map of the seven chromosomes of the diploid Fragaria iinumae, which allows them to fill in a piece of the genetic puzzle about the eight sets of chromosomes of the cultivated strawberry.
Progress In Vaccination Against Vespid Venom
Researchers at the Helmholtz Zentrum München and the Technical University Munich have presented a method which facilitates a personalised procedure for wasp allergy sufferers.
New Drug Target for Inflammatory Disorders
Penn study finds enigmatic molecules maintain equilibrium between fighting infection and inflammatory havoc.
Breast Cancer Cells Found To Switch Molecular Characteristics
Spontaneous interconversion between HER2-positive and HER2-negative states could contribute to progression, treatment resistance in breast cancer.
Mechanisms of Calcium Blockers
Researchers describe how the fundamental mode of action of two distinct chemical classes of calcium channel blockers differs.
Some Breast Cancer Patients With Low Genetic Risk Could Skip Chemotherapy
Genetic test can help predict survival and guide treatment options.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!